Streetbeat News

BHVN

Biohaven Ltd.

https://www.biohaven.com/

Industry

Biotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Open

28.76

Mkt cap

3B

Volume

654K

High

29.65

P/E Ratio

-3.14

52-wk high

60.46

Low

28.52

Div yield

N/A

52-wk low

26.80

Biohaven has initiated a pivotal Phase 2 study for its TRPM3 antagonist, BHV-2100, aimed at treating acute migraines. The trial will assess the efficacy and safety of two doses and is designed to support FDA registration.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:34 am

Several US-listed stocks saw significant gains on Wednesday, with Hewlett Packard Enterprise (HPE) rising 5.5% after a Barclays upgrade. Progress Software (PRGS) and Nvidia (NVDA) also saw notable increases due to positive analyst actions and strategic moves.

Portfolio Pulse from Avi Kapoor

September 25, 2024 | 2:13 pm

Bernstein analyst William Pickering has maintained an 'Outperform' rating on Biohaven (NYSE:BHVN) and raised the price target from $55 to $66.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 5:06 pm

B of A Securities has maintained its Buy rating on Biohaven and increased the price target from $52 to $62, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:17 pm

RBC Capital analyst Leonid Timashev has maintained an 'Outperform' rating on Biohaven (NYSE:BHVN) and raised the price target from $59 to $68.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:46 pm

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Biohaven (NYSE:BHVN).

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:30 pm

HC Wainwright & Co. has reiterated its Buy rating on Biohaven (NYSE:BHVN) and maintained a price target of $59, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 10:50 am

U.S. stocks rose with the Dow gaining over 50 points. Kaival Brands surged 148% after a merger announcement, while Elevai Labs plummeted 63% following a public offering pricing. BitFuFu and Biohaven also saw significant gains. MINISO fell 17% after a downgrade.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 6:35 pm

Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Biohaven (NYSE:BHVN) and raised the price target from $66 to $76.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 6:00 pm

The article highlights unusual options activity in the health care sector, focusing on large transactions by 'whales' in various stocks. Notable mentions include bullish call sweeps for Pfizer (PFE), BioNTech (BNTX), and MannKind (MNKD), and bearish put sweeps for TG Therapeutics (TGTX) and Globus Medical (GMED).

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 5:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.